Sun Pharma Advanced Research Company Limited (SPARC.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹179.24 (+0.47%) as of
Key statistics
- Market cap
- 58.17B
- P/E (TTM)
- 3.67
- Forward P/E
- 3.24
- EPS (TTM)
- 48.81
- Dividend yield
- 0.00%
- 52-week range
- 108.00 – 289.00
- Beta
- 0.65
- Revenue (TTM)
- 19.09B
- Profit margin
- 82.97%
- Volume
- 514.93k
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 279
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.